Literature DB >> 34199535

Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives.

Michele Finotti1, Maurizio Romano1, Pasquale Auricchio2, Michele Scopelliti1, Marco Brizzolari1, Ugo Grossi1, Marco Piccino1, Stefano Benvenuti3, Giovanni Morana4, Umberto Cillo2, Giacomo Zanus1.   

Abstract

Non-alcoholic fatty liver disease represents an increasing cause of chronic hepatic disease in recent years. This condition usually arises in patients with multiple comorbidities, the so-called metabolic syndrome. The therapeutic options are multiple, ranging from lifestyle modifications, pharmacological options, to liver transplantation in selected cases. The choice of the most beneficial one and their interactions can be challenging. It is mandatory to stratify the patients according to the severity of their disease to tailor the available treatments. In our contribution, we review the most recent pharmacological target therapies, the role of bariatric surgery, and the impact of liver transplantation on the NAFLD outcome.

Entities:  

Keywords:  bariatric surgery; liver transplantation; non-alcoholic fatty liver disease

Year:  2021        PMID: 34199535     DOI: 10.3390/jpm11060499

Source DB:  PubMed          Journal:  J Pers Med        ISSN: 2075-4426


  3 in total

1.  Personalized Medicine for Liver Disease: From Molecular Mechanisms to Potential Targeted Therapies.

Authors:  Aaron W Bell
Journal:  J Pers Med       Date:  2022-04-21

2.  Study on Syndrome Intervention of Nonalcoholic Fatty Liver Disease from the Perspective of Deficiency and Excess.

Authors:  Sanhang Wang; Hu Jiu Lüe; Jiao Zhao
Journal:  J Healthc Eng       Date:  2021-09-15       Impact factor: 2.682

Review 3.  Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.

Authors:  Koichi Yabiku
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-07       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.